

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT8330292

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
WEI WANG	10/30/2019
E-CHIANG LEE	10/30/2019
JOHN BLACKWOOD	10/30/2019
ROBERTO MAGLIOZZI	10/30/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	KYMAB LIMITED
<b>Street Address:</b>	THE BENNET BUILDING (B930)
<b>Internal Address:</b>	BABRAHAM RESEARCH CAMPUS
<b>City:</b>	CAMBRIDGE
<b>State/Country:</b>	UNITED KINGDOM
<b>Postal Code:</b>	CB22 3AT
<b>PROPERTY NUMBERS Total: 3</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	16722452
Application Number:	17063905
Application Number:	17311595
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(857)300-4001
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(857) 300-4000
<b>Email:</b>	leslie.roberts@lathropgpm.com, internalip@lathropgpm.com
<b>Correspondent Name:</b>	LATHROP GPM LLP
<b>Address Line 1:</b>	28 STATE STREET
<b>Address Line 2:</b>	7TH FLOOR
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02109
<b>ATTORNEY DOCKET NUMBER:</b>	SA9-625 FAMILY
<b>NAME OF SUBMITTER:</b>	JAMES H. VELEMA, ESQ.
<b>SIGNATURE:</b>	/James H. Velema/
<b>DATE SIGNED:</b>	12/14/2023

**Total Attachments: 5**

source=719070- SA9-625US - Executed Assignment#page1.tif

source=719070- SA9-625US - Executed Assignment#page2.tif

source=719070- SA9-625US - Executed Assignment#page3.tif

source=719070- SA9-625US - Executed Assignment#page4.tif

source=719070- SA9-625US - Executed Assignment#page5.tif

**PATENT**

**REEL: 065868 FRAME: 0475**

CONFIRMATORY ASSIGNMENT

WHEREAS, We, Wei WANG, E-Chiang LEE, John Kenneth BLACKWOOD and Roberto MAGLIOZZI have invented certain improvements in **FIXaxFX Bispecific Antibody with Common Light Chain** (“the Invention”) described in various applications for Patents, including:

- 1) United Kingdom patent applications GB1820977.5 filed on 21<sup>st</sup> December 2018, GB1906816.2 filed on 15<sup>th</sup> May 2019 & GB1908190.0 filed on 07<sup>th</sup> June 2019, entitled **FIXaxFX Bispecific Antibody with Common Light Chain** and having Kymab internal references K00058-1 GB, K00058-2 GB & K00058-3 GB respectively;
- 2) a Patent Cooperation Treaty application, which will designate *inter alia* the United States of America and which will be filed on or before 21<sup>st</sup> December 2019, having Kymab internal reference K00058-1 WO and claiming priority from the UK patent applications identified above; and
- 3) a Taiwanese patent application, which is entitled “FIXaxFX Bispecific Antibody with Common Light Chain” and which will be filed on or before 21<sup>st</sup> December 2019, having Kymab internal reference K00058-1 TW and claiming priority from the UK patent applications identified above;

WHEREAS, **Kymab Limited** (hereinafter “ASSIGNEE”), a corporation organised and existing under the laws of England, and having a usual place of business at **Bennet Building (B930), Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom** has acquired and hereby does acquire the entire right, title, and interest therein in accordance with agreements duly entered into with us;

NOW, THEREFORE, to all whom it may concern be it known that for and in consideration of said agreements and of other good and valuable consideration, the receipt of and sufficiency of which is hereby acknowledged, We confirm having sold, assigned and transferred the right, title and interest by virtue of our agreements, and do hereby sell, assign and transfer any remaining right, title and interest, in and to the invention unto said ASSIGNEE, its successors, assigns and legal representatives, in and throughout the United States of America, its territories and in all international and foreign jurisdictions including Canada, including all priority applications that describe the invention, the right of priority (and the right to claim priority from previously-filed applications), the applications identified herein, and any and all additional and/or further applications (including, without limitation, substitution, divisional, renewal, reissue, re-examination and continuation applications), extensions thereof and supplementary protection certificates that claim and/or disclose the invention, together with our entire right, title and interest in and to said applications, extensions and certificates and such Letters Patent as may issue on said invention; said invention, applications, extensions, certificates and Letters Patent to be held and enjoyed by said ASSIGNEE for its own use and

behalf and for its successors, assigns and legal representatives, to the full end of the term for which said Letters Patent, extensions and certificates may be granted as fully and entirely as the same would have been held by us had the rights not been assigned; We hereby convey all rights arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for Letters Patent, extensions or certificates. We hereby acknowledge that this assignment, being of our entire right, title and interest in and to said invention, carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world (including in Canada and the United States of America) any and all Letters Patent, extensions and certificates by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all such Letters Patent, extensions and certificates to ASSIGNEE for its own name as assignee of the entire right, title and interest therein; We hereby expressly authorise the filing of any patent application under the Patent Cooperation Treaty, European Patent Convention or any other national or regional patent law or treaty, which corresponds to and/or claims the priority of the above-identified application;

UPON SAID CONSIDERATIONS, We hereby agree with the said ASSIGNEE that We will not execute any writing or do any act whatsoever conflicting with these presents, and that we have the full right to convey the interests mentioned herein;

AND, We hereby further agree for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid invention to said ASSIGNEE, its successors, assigns and legal representatives, for no additional consideration but at its or their expense and charges, including the execution of applications for patents in foreign countries, and the execution of any further applications including substitution, divisional, reissue, re-examination or continuation applications or extensions thereof or supplementary protection certificates, and preliminary or other statements and the giving of all necessary assistance and testimony in any interference, inter-partes review, post-grant review, opposition, re-examination or other proceedings or transactions in which said invention or any application or patent directed thereto may be involved;

AND, We do hereby authorise and request each Patent Office and the Commissioner of Patents of the United States or other authority of a foreign jurisdiction to issue such Letters Patent, extensions and certificates as shall be granted upon said invention to ASSIGNEE, its successors, assigns and legal representatives;

AND, We hereby grant ASSIGNEE, its legal representatives, successors and assigns the power to insert on this instrument any further identification that may be necessary or desirable to comply with the recordation rules of any appropriate and competent authority, including, without limitation, the United States Patent and Trademark Office;

AND, We hereby agree that this Assignment may be executed in two or more counterparts each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Inventor Wei Wang Date 30/10/2019  
Wei WANG

Address C/O Kymab Ltd, The Bennet Building (B930),  
Babraham Research Campus, Cambridge, CB22 3AT

Witness Signature [Signature]

Print Witness Name PAUL NESBIT

Address C/O Kymab Ltd, The Bennet Building (B930),  
Babraham Research Campus, Cambridge, CB22 3AT

Witness Signature P Keen

Print Witness Name PKEEN

Address C/O Kymab Ltd, The Bennet Building (B930),  
Babraham Research Campus, Cambridge, CB22 3AT

Inventor E-Chiang LEE Date 30/10/2019  
E-Chiang LEE

Address C/O Kymab Ltd, The Bennet Building (B930),  
Babraham Research Campus, Cambridge, CB22 3AT

Witness Signature [Signature]


Print Witness Name PAUL NESBIT

Address C/O Kymab Ltd, The Bennet Building (B930),  
Babraham Research Campus, Cambridge, CB22 3AT

Witness Signature P Keen

Print Witness Name PKEEN

Address C/O Kymab Ltd, The Bennet Building (B930),  
Babraham Research Campus, Cambridge, CB22 3AT

Inventor  Date 30/10/2019  
John BLACKWOOD

Address C/O Kymab Ltd, The Bennet Building (B930),  
Babraham Research Campus, Cambridge, CB22 3AT

Witness Signature 

Print Witness Name PAUL NESBIT

Address C/O Kymab Ltd, The Bennet Building (B930),  
Babraham Research Campus, Cambridge, CB22 3AT

Witness Signature P Keen

Print Witness Name P KEEN

Address C/O Kymab Ltd, The Bennet Building (B930),  
Babraham Research Campus, Cambridge, CB22 3AT

Inventor  Date 30/10/2019  
Roberto MAGLIOZZI

Address C/O Kymab Ltd, The Bennet Building (B930),  
Babraham Research Campus, Cambridge, CB22 3AT

Witness Signature 

Print Witness Name PAUL NESBIT


Address C/O Kymab Ltd, The Bennet Building (B930),  
Babraham Research Campus, Cambridge, CB22 3AT

Witness Signature P Keen

Print Witness Name P KEEN

Address C/O Kymab Ltd, The Bennet Building (B930),  
Babraham Research Campus, Cambridge, CB22 3AT

Kymab Limited,

By 

Glenn Friedrich


Typed or Printed Name

Chief Operating Officer

Title

31<sup>st</sup> OCTOBER 2019


Date

Witness Signature 

Print Witness Name PAUL NESBIT

Address C/O Kymab Ltd, The Bennet Building (B930),

Babraham Research Campus, Cambridge, CB22 3AT

Witness Signature 

Print Witness Name P KEEN

Address C/O Kymab Ltd, The Bennet Building (B930),

Babraham Research Campus, Cambridge, CB22 3AT